Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
Identifieur interne : 002F48 ( Main/Exploration ); précédent : 002F47; suivant : 002F49Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
Auteurs : Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Source :
- Movement disorders [ 0885-3185 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Autoradiography, Biological transport, Brain (metabolism), Case-Control Studies, Catecholamine, Chemotherapy, Dopamine, Dopamine (metabolism), Dyskinesia, Dyskinesia, Drug-Induced (metabolism), Dyskinesia, Drug-Induced (physiopathology), Female, Gabaergic receptor, Globus Pallidus (metabolism), Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Mechanism of action, Metabolism, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Postmortem Changes, Receptors, GABA (metabolism), Receptors, GABA-A (metabolism), Receptors, GABA-B (metabolism), Toxicity, Treatment.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , metabolism : Dopamine, Receptors, GABA, Receptors, GABA-A, Receptors, GABA-B.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Dyskinesia, Drug-Induced, Globus Pallidus, Parkinson Disease.
- physiopathology : Dyskinesia, Drug-Induced.
- Aged, Aged, 80 and over, Autoradiography, Case-Control Studies, Female, Humans, Male, Postmortem Changes.
Abstract
Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-125I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([125I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal 35S-labeled t-butylbicyclophosphorothionate ([35S]TBPS) and [3H]flunitrazepam binding to GABAA receptors were unchanged in patients with Parkinsons disease, whereas [125I]CGP 64213 -specific binding to GABAB receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [3H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [35S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABAA receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABAA receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000A79
- to stream PascalFrancis, to step Curation: 000244
- to stream PascalFrancis, to step Checkpoint: 000971
- to stream Main, to step Merge: 003357
- to stream PubMed, to step Corpus: 001451
- to stream PubMed, to step Curation: 001451
- to stream PubMed, to step Checkpoint: 001451
- to stream Ncbi, to step Merge: 000284
- to stream Ncbi, to step Curation: 000284
- to stream Ncbi, to step Checkpoint: 000284
- to stream Main, to step Merge: 003188
- to stream Main, to step Curation: 002F48
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0238134</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0238134 INIST</idno>
<idno type="RBID">Pascal:03-0238134</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A79</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000244</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000971</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000971</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Calon F:changes:of:gaba</idno>
<idno type="wicri:Area/Main/Merge">003357</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12621627</idno>
<idno type="wicri:Area/PubMed/Corpus">001451</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001451</idno>
<idno type="wicri:Area/PubMed/Curation">001451</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001451</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001451</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001451</idno>
<idno type="wicri:Area/Ncbi/Merge">000284</idno>
<idno type="wicri:Area/Ncbi/Curation">000284</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000284</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Calon F:changes:of:gaba</idno>
<idno type="wicri:Area/Main/Merge">003188</idno>
<idno type="wicri:Area/Main/Curation">002F48</idno>
<idno type="wicri:Area/Main/Exploration">002F48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Autoradiography</term>
<term>Biological transport</term>
<term>Brain (metabolism)</term>
<term>Case-Control Studies</term>
<term>Catecholamine</term>
<term>Chemotherapy</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (metabolism)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Female</term>
<term>Gabaergic receptor</term>
<term>Globus Pallidus (metabolism)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Mechanism of action</term>
<term>Metabolism</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Postmortem Changes</term>
<term>Receptors, GABA (metabolism)</term>
<term>Receptors, GABA-A (metabolism)</term>
<term>Receptors, GABA-B (metabolism)</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Receptors, GABA</term>
<term>Receptors, GABA-A</term>
<term>Receptors, GABA-B</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Globus Pallidus</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Autoradiography</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Postmortem Changes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Récepteur gabaergique</term>
<term>Autoradiographie</term>
<term>Dopamine</term>
<term>Transport biologique</term>
<term>Catécholamine</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Mécanisme action</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Métabolisme</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-<sup>125</sup>
I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([<sup>125</sup>
I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal <sup>35</sup>
S-labeled t-butylbicyclophosphorothionate ([<sup>35</sup>
S]TBPS) and [<sup>3</sup>
H]flunitrazepam binding to GABA<sub>A</sub>
receptors were unchanged in patients with Parkinsons disease, whereas [<sup>125</sup>
I]CGP 64213 -specific binding to GABA<sub>B</sub>
receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [<sup>3</sup>
H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [<sup>35</sup>
S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABA<sub>A</sub>
receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABA<sub>A</sub>
receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Canada</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
</noRegion>
<name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:03-0238134 |texte= Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications }}
This area was generated with Dilib version V0.6.29. |